A new COVID-19 vaccine has achieved 100 percent efficacy against severe disease and hospitalizations, announced manufacturers Sanofi and GSK on Wednesday. The companies are now set to apply for regulatory authorization from bodies like the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to release the vaccine as both a two-dose vaccine and booster shot. Unlike vaccines based on mRNA technology, the new Sanofi-GSK offering is a protein-based vaccine – a “well-established approach that has been applied widely to prevent infection with other viruses including pandemic flu,” said GSK President Roger Connor in a statement today. “We...